Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ThredUp Inc (TDUP) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

ThredUp (TDUP) trades at $6.60, up 0.38% on the day, with a bullish technical signal and strong analyst support (57% buy ratings). The company reported Q1 2026 revenue of $81.7 million, a 15% year-over-year increase, and a gross margin of 79.2%, though net losses persist. Recent initiatives include launching a peer-to-peer marketplace and AI-driven shopping tools to boost growth.

The outlook is cautiously optimistic, with a consensus price target of $6.90 offering modest upside. Key opportunities lie in margin improvement and AI efficiency gains, but risks include sustained profitability challenges and competitive pressures in online resale. Investors should weigh growth potential against ongoing losses.